Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Unknown 2Terminated 2Recruiting 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 2

Conditions

Triple Negative Breast Neoplasms 2Leukemia, Myeloid, Acute 2Breast Neoplasms 2HER2-negative Breast Cancer 1Cardiotoxicity 1

Interventions

Fulvestrant 58Trastuzumab 49Capecitabine 48Letrozole 45pembrolizumab 41Carboplatin 41Paclitaxel 39Cyclophosphamide 38ribociclib 37pertuzumab 36abemaciclib 36Blood Specimen Collection 31Specimen Handling 28trastuzumab deruxtecan 27Docetaxel 27Surveys and Questionnaires 26Anastrozole 25exemestane 24Tamoxifen 24palbociclib 21130-nm albumin-bound paclitaxel 21Magnetic Resonance Spectroscopy 20Biopsy 19sacituzumab govitecan 18eribulin 18Radiotherapy 18Gemcitabine 18olaparib 17Injections 17Epirubicin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Breast Neoplasms × Anthracyclines × Clear all
NCT06802757 2026-02-25

PRISM-TNBC

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
72 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06443645 2026-02-04

SCARA-B

Centre Paul Strauss

Recruiting
50 enrolled
Breast

Breast Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡